Multiple analogs of Rapa (temsirolimus and everolimus) have been approved by the FDA for the clinical treatment of subependymal giant cell astrocytoma (SEGA), advanced hormone receptor–positive HER2-negative breast cancer, primitive neuroectodermal tumors (PNETs) of pancreatic origin, and for advanced renal cell carcinoma (RCC) [18, 19] (see also the National Institutes of Health-National Cancer Institute website). Here, NR4A1 is linked to subependymal giant cell astrocytoma.